Literature DB >> 23179944

Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.

Brusabhanu Nayak1, Prem Nath Dogra, Niraj Naswa, Rakesh Kumar.   

Abstract

PURPOSE: Positron emission tomography/computed tomography (PET/CT) with (18)F-fluorodeoxyglucose (FDG) has been used with limited success in the past in primary diagnosis and locoregional staging of urinary bladder cancer, mainly because of the pharmacokinetics of renal excretion of (18)F-FDG. In the present prospective study, we have evaluated the potential application of diuretic (18)F-FDG PET/CT in improving detection and locoregional staging of urinary bladder tumours.
METHODS: Twenty-five patients suspected of having primary carcinoma of the urinary bladder were evaluated prospectively for diagnosis and staging. All of these 25 patients underwent conventional contrast-enhanced computed tomography (CECT) of the abdomen/pelvis and whole-body diuretic (18)F-FDG PET/CT. In addition, pelvic PET/CT images were obtained using the special technique of forced diuresis using intravenous furosemide (20-40 mg). Of the 25 patients, 10 underwent radical cystectomy and 15 underwent transurethral resection of the bladder tumour (TURBT). Results of CECT and diuretic (18)F-FDG PET/CT were compared considering histopathology as a reference standard.
RESULTS: Of the 25 patients, CECT detected a primary tumour in 23 (sensitivity 92 %), while (18)F-FDG PET/CT was positive in 24 patients (sensitivity 96 %). Mean size and maximum standardized uptake value of the bladder tumours were 3.33 cm (range 1.6-6.2) and 5.3 (range 1.3-11.7), respectively. Of the 25 patients, only 10 patients underwent radical cystectomy based on disease status on TURBT. Among those ten patients, nine had locoregional metastases. Among the nine patients who had positive lymph nodes for metastasis on histopathology, CECT and PET/CT scan had a sensitivity of 44 and 78 %, respectively. (18)F-FDG PET/CT was found to be superior to CECT in the detection of the primary tumour and locoregional staging (p < 0.05).
CONCLUSION: Diuretic (18)F-FDG PET/CT is highly sensitive and specific and plays an important role in improving detection of the primary tumour and locoregional staging of urinary bladder tumours. Diuretic (18)F-FDG PET/CT demonstrated a higher diagnostic value when compared with CECT in these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23179944     DOI: 10.1007/s00259-012-2294-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  18 in total

1.  Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity.

Authors:  Yan Xiu; Chirdeep Bhutani; Thiruvenkatasamy Dhurairaj; Jian Q Yu; Simin Dadparvar; Swapna Reddy; Rakesh Kumar; Hua Yang; Abass Alavi; Hongming Zhuang
Journal:  Clin Nucl Med       Date:  2007-02       Impact factor: 7.794

2.  Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.

Authors:  Andrea B Apolo; Jamie Riches; Heiko Schöder; Oguz Akin; Alisa Trout; Matthew I Milowsky; Dean F Bajorin
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

3.  FDG-PET for preoperative staging of bladder cancer.

Authors:  O Drieskens; R Oyen; H Van Poppel; Y Vankan; P Flamen; L Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-31       Impact factor: 9.236

4.  Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies.

Authors:  Ehab M Kamel; Patrice Jichlinski; John O Prior; Jean-Yves Meuwly; Jean-Francois Delaloye; Laurent Vaucher; Jerome Malterre; Sandra Castaldo; Hans-Juerg Leisinger; Angelika Bischof Delaloye
Journal:  J Nucl Med       Date:  2006-11       Impact factor: 10.057

5.  Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging.

Authors:  B Kim; R C Semelka; S M Ascher; D B Chalpin; P R Carroll; H Hricak
Journal:  Radiology       Date:  1994-10       Impact factor: 11.105

Review 6.  From the Archives of the AFIP: neoplasms of the urinary bladder: radiologic-pathologic correlation.

Authors:  Jade J Wong-You-Cheong; Paula J Woodward; Maria A Manning; Isabell A Sesterhenn
Journal:  Radiographics       Date:  2006 Mar-Apr       Impact factor: 5.333

Review 7.  Computer tomography and magnetic resonance imaging in the evaluation of bladder cancer.

Authors:  J E Husband
Journal:  J Belge Radiol       Date:  1995-12

8.  Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography.

Authors:  J V Harney; R L Wahl; M Liebert; D E Kuhl; G D Hutchins; G Wedemeyer; H B Grossman
Journal:  J Urol       Date:  1991-02       Impact factor: 7.450

9.  FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.

Authors:  Greet Swinnen; Alex Maes; Hans Pottel; Alain Vanneste; Ignace Billiet; Karl Lesage; Patrick Werbrouck
Journal:  Eur Urol       Date:  2009-05-18       Impact factor: 20.096

10.  Computerized tomography: an unreliable method for accurate staging of bladder tumors in patients who are candidates for radical cystectomy.

Authors:  G E Voges; E Tauschke; M Stöckle; P Alken; R Hohenfellner
Journal:  J Urol       Date:  1989-10       Impact factor: 7.450

View more
  30 in total

Review 1.  Preoperative Imaging for Clinical Staging Prior to Radical Cystectomy.

Authors:  Cory M Hugen; Vinay Duddalwar; Siamak Daneshmand
Journal:  Curr Urol Rep       Date:  2016-09       Impact factor: 3.092

2.  Diagnostic value of [18F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysis.

Authors:  Huojun Zhang; Wei Xing; Qinqin Kang; Chao Chen; Linhui Wang; Jianping Lu
Journal:  Tumour Biol       Date:  2015-03-26

Review 3.  Update on use of enhanced imaging to optimize lymphadenectomy in patients undergoing minimally invasive surgery for urothelial cancer of the bladder.

Authors:  Lukas Lusuardi; Günter Janetschek
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

4.  Diuretic ¹⁸F-FDG PET/CT for therapy monitoring in urothelial bladder cancer.

Authors:  Elodie Coquan; Charline Lasnon; Florence Joly; Jean-Marc Lefort; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06-04       Impact factor: 9.236

5.  Comparison of Coregistration Accuracy of Pelvic Structures Between Sequential and Simultaneous Imaging During Hybrid PET/MRI in Patients with Bladder Cancer.

Authors:  Andrew B Rosenkrantz; Arjun V Balar; William C Huang; Kimberly Jackson; Kent P Friedman
Journal:  Clin Nucl Med       Date:  2015-08       Impact factor: 7.794

6.  The role and effect of FDG-PET/CT on patient management and restaging of bladder carcinoma.

Authors:  İsa Burak Güney; Kadir Alper Küçüker; Volkan İzol; Mustafa Kibar
Journal:  Turk J Urol       Date:  2019-11-01

7.  68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging.

Authors:  Thorsten Derlin; Desiree Weiberg; Christoph von Klot; Hans-Jürgen Wester; Christoph Henkenberens; Tobias L Ross; Hans Christiansen; Axel S Merseburger; Frank M Bengel
Journal:  Eur Radiol       Date:  2016-03-24       Impact factor: 5.315

8.  Positron emission tomography/computed tomography imaging features of renal cell carcinoma and pulmonary metastases in a dog.

Authors:  Sun-Hye Song; Noh-Won Park; Ki-Dong Eom
Journal:  Can Vet J       Date:  2014-05       Impact factor: 1.008

9.  The influence of post-diuretic late phase imaging in visual and quantitative evaluation of urothelial tumors by F-18 fluorodeoxyglucose positron emission tomography/computed tomography.

Authors:  Zehra Pınar Koç; Pelin Özcan Kara; Emel Sezer; Kadir Eser
Journal:  Turk J Urol       Date:  2019-12-01

Review 10.  Current Status of Hybrid PET/MRI in Oncologic Imaging.

Authors:  Andrew B Rosenkrantz; Kent Friedman; Hersh Chandarana; Amy Melsaether; Linda Moy; Yu-Shin Ding; Komal Jhaveri; Luis Beltran; Rajan Jain
Journal:  AJR Am J Roentgenol       Date:  2015-10-22       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.